93 related articles for article (PubMed ID: 17846226)
21. Targeted therapy for Kaposi sarcoma.
Sullivan RJ; Pantanowitz L; Dezube BJ
BioDrugs; 2009; 23(2):69-75. PubMed ID: 19489649
[TBL] [Abstract][Full Text] [Related]
22. Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice.
Basile LA; Gallaher TK; Shibata D; Miller JD; Douer D
J Transl Med; 2008 May; 6():26. PubMed ID: 18489769
[TBL] [Abstract][Full Text] [Related]
23. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
Coukell AJ; Spencer CM
Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
[TBL] [Abstract][Full Text] [Related]
24. Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.
Yarchoan R; Pluda JM; Wyvill KM; Aleman K; Rodriguez-Chavez IR; Tosato G; Catanzaro AT; Steinberg SM; Little RF
Crit Rev Immunol; 2007; 27(5):401-14. PubMed ID: 18197804
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.
Little RF; Aleman K; Kumar P; Wyvill KM; Pluda JM; Read-Connole E; Wang V; Pittaluga S; Catanzaro AT; Steinberg SM; Yarchoan R
Blood; 2007 Dec; 110(13):4165-71. PubMed ID: 17846226
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
[TBL] [Abstract][Full Text] [Related]
27. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
Northfelt DW; Dezube BJ; Thommes JA; Miller BJ; Fischl MA; Friedman-Kien A; Kaplan LD; Du Mond C; Mamelok RD; Henry DH
J Clin Oncol; 1998 Jul; 16(7):2445-51. PubMed ID: 9667262
[TBL] [Abstract][Full Text] [Related]
28. A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.
Ramaswami R; Uldrick TS; Polizzotto MN; Wyvill KM; Goncalves P; Widell A; Lurain K; Steinberg SM; Figg WD; Tosato G; Whitby D; Yarchoan R
Clin Cancer Res; 2019 Jul; 25(14):4238-4247. PubMed ID: 30979736
[TBL] [Abstract][Full Text] [Related]
29. Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study.
Dalu D; Fasola C; Ammoni L; De Francesco D; Cona MS; Rota S; Ferrario S; Gambaro A; Tosca N; Piva S; La Verde N
J Chemother; 2021 Sep; 33(5):342-347. PubMed ID: 34060438
[TBL] [Abstract][Full Text] [Related]
30. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.
Little RF; Pluda JM; Wyvill KM; Rodriguez-Chavez IR; Tosato G; Catanzaro AT; Steinberg SM; Yarchoan R
Blood; 2006 Jun; 107(12):4650-7. PubMed ID: 16507779
[TBL] [Abstract][Full Text] [Related]
31. Therapy insight: AIDS-related malignancies--the influence of antiviral therapy on pathogenesis and management.
Yarchoan R; Tosato G; Little RF
Nat Clin Pract Oncol; 2005 Aug; 2(8):406-15; quiz 423. PubMed ID: 16130937
[TBL] [Abstract][Full Text] [Related]
32. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
[TBL] [Abstract][Full Text] [Related]
33. Survival after cancer diagnosis in persons with AIDS.
Biggar RJ; Engels EA; Ly S; Kahn A; Schymura MJ; Sackoff J; Virgo P; Pfeiffer RM
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):293-9. PubMed ID: 15980688
[TBL] [Abstract][Full Text] [Related]
34. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Noy A; Scadden DT; Lee J; Dezube BJ; Aboulafia D; Tulpule A; Walmsley S; Gill P
J Clin Oncol; 2005 Feb; 23(5):990-8. PubMed ID: 15598977
[TBL] [Abstract][Full Text] [Related]
35. Quantitative assessment of tumor vasculature and response to therapy in kaposi's sarcoma using functional noninvasive imaging.
Hassan M; Little RF; Vogel A; Aleman K; Wyvill K; Yarchoan R; Gandjbakhche AH
Technol Cancer Res Treat; 2004 Oct; 3(5):451-7. PubMed ID: 15453810
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
